Compare AstraZeneca plc (AZN) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Futu Holdings Ltd — how do they compare? AstraZeneca plc trades at $158.41 (market cap $248.14B), while Futu Holdings Ltd trades at $105.41 (market cap $14.74B). The key difference: AstraZeneca plc is far larger — about 16.8× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays the higher dividend (2.47%). Which is the better fit depends on your goals.
| AZN | FUTU | |
|---|---|---|
Market Cap | $248.14B | $14.74B |
Sector | Health | Financials |
52-Week High | $209.48 | $199.04 |
52-Week Low | $147.06 | $89.76 |
Enterprise Value | $275.41B | $14.59B |
Dividend Yield | 2.01% | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
FUTU trades at $105.41, down 3.03% today, amid a securities class action filing alleging regulatory compliance failures. The stock shows strong fundamentals with a P/E of 11.63 and net income margin of 41.83%, supported by robust revenue growth from $13.6B in 2024 to $22.85B in 2025. Technical indicators are bullish on moving averages, with key support at $103 and resistance at $110.
The outlook is mixed: strong profitability and analyst consensus (58% buy ratings) support upside, but legal risks and recent earnings misses pose significant headwinds. Investors should weigh solid financials against litigation overhang and market sentiment pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
